Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $142.01 billion. The enterprise value is $188.73 billion.
Important Dates
The next confirmed earnings date is Tuesday, April 29, 2025, before market open.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | Jan 24, 2025 |
Share Statistics
Pfizer has 5.67 billion shares outstanding. The number of shares has decreased by -0.16% in one year.
| Current Share Class | 5.67B |
| Shares Outstanding | 5.67B |
| Shares Change (YoY) | -0.16% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 67.12% |
| Float | 5.66B |
Valuation Ratios
The trailing PE ratio is 17.73 and the forward PE ratio is 8.49. Pfizer's PEG ratio is 3.32.
| PE Ratio | 17.73 |
| Forward PE | 8.49 |
| PS Ratio | 2.24 |
| Forward PS | 2.22 |
| PB Ratio | 1.62 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.42 |
| P/OCF Ratio | 11.13 |
| PEG Ratio | 3.32 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.09, with an EV/FCF ratio of 19.19.
| EV / Earnings | 23.50 |
| EV / Sales | 2.97 |
| EV / EBITDA | 8.09 |
| EV / EBIT | 11.56 |
| EV / FCF | 19.19 |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.76.
| Current Ratio | 1.17 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | 2.75 |
| Debt / FCF | 6.85 |
| Interest Coverage | 5.28 |
Financial Efficiency
Return on equity (ROE) is 9.06% and return on invested capital (ROIC) is 6.37%.
| Return on Equity (ROE) | 9.06% |
| Return on Assets (ROA) | 4.64% |
| Return on Invested Capital (ROIC) | 6.37% |
| Return on Capital Employed (ROCE) | 9.58% |
| Revenue Per Employee | $785,519 |
| Profits Per Employee | $99,148 |
| Employee Count | 81,000 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.56 |
Taxes
| Income Tax | -28.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.86% in the last 52 weeks. The beta is 0.54, so Pfizer's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -9.86% |
| 50-Day Moving Average | 26.06 |
| 200-Day Moving Average | 27.53 |
| Relative Strength Index (RSI) | 37.19 |
| Average Volume (20 Days) | 56,394,755 |
Short Selling Information
The latest short interest is 99.17 million, so 1.75% of the outstanding shares have been sold short.
| Short Interest | 99.17M |
| Short Previous Month | 89.12M |
| Short % of Shares Out | 1.75% |
| Short % of Float | 1.75% |
| Short Ratio (days to cover) | 2.34 |
Income Statement
In the last 12 months, Pfizer had revenue of $63.63 billion and earned $8.03 billion in profits. Earnings per share was $1.41.
| Revenue | 63.63B |
| Gross Profit | 47.21B |
| Operating Income | 16.33B |
| Pretax Income | n/a |
| Net Income | 8.03B |
| EBITDA | 23.32B |
| EBIT | 16.33B |
| Earnings Per Share (EPS) | $1.41 |
Full Income StatementBalance Sheet
The company has $20.48 billion in cash and $67.42 billion in debt, giving a net cash position of -$46.94 billion or -$8.28 per share.
| Cash & Cash Equivalents | 20.48B |
| Total Debt | 67.42B |
| Net Cash | -46.94B |
| Net Cash Per Share | -$8.28 |
| Equity (Book Value) | 88.50B |
| Book Value Per Share | 15.56 |
| Working Capital | 7.36B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $12.74 billion and capital expenditures -$2.91 billion, giving a free cash flow of $9.84 billion.
| Operating Cash Flow | 12.74B |
| Capital Expenditures | -2.91B |
| Free Cash Flow | 9.84B |
| FCF Per Share | $1.73 |
Full Cash Flow StatementMargins
Gross margin is 74.19%, with operating and profit margins of 25.66% and 12.62%.
| Gross Margin | 74.19% |
| Operating Margin | 25.66% |
| Pretax Margin | 12.61% |
| Profit Margin | 12.62% |
| EBITDA Margin | 36.65% |
| EBIT Margin | 25.66% |
| FCF Margin | 15.46% |
Dividends & Yields
This stock pays an annual dividend of $1.72, which amounts to a dividend yield of 6.87%.
| Dividend Per Share | $1.72 |
| Dividend Yield | 6.87% |
| Dividend Growth (YoY) | 2.42% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 121.82% |
| Buyback Yield | 0.16% |
| Shareholder Yield | 7.04% |
| Earnings Yield | 5.66% |
| FCF Yield | 6.94% |
Dividend DetailsAnalyst Forecast
The average price target for Pfizer is $31.92, which is 27.48% higher than the current price. The consensus rating is "Buy".
| Price Target | $31.92 |
| Price Target Difference | 27.48% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | -2.15% |
| EPS Growth Forecast (5Y) | 13.45% |
Stock ForecastsStock Splits
The last stock split was on July 1, 1999. It was a forward split with a ratio of 3:1.
| Last Split Date | Jul 1, 1999 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Pfizer has an Altman Z-Score of 2.12 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.12 |
| Piotroski F-Score | 8 |